This paper critiques the haematological monitoring guidelines for clozapine. It describes the history of clozapine, as well as the pathophysiology and epidemiology of clozapine-induced neutropenia (CIN) and agranulocytosis (CIA). The paper appraises the extant literature on mandatory clozapine haematological monitoring.
Conclusion
Contemporary Australian protocols for clozapine haematological monitoring are not consistent with the current evidence base. CIN and CIA are rare occurrences, and the associated risk of death is low. Potential modifications to existing guidelines include changing neutrophil thresholds for patients with benign ethnic neutropenia and reducing the frequency or removing haematological monitoring after two years of clozapine treatment.
SiskindDMcCartneyLGoldschlagerR, et al.Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry2016; 209: 385–392. DOI: 10.1192/bjp.bp.115.177261.
2.
VermeulenJMvan RooijenGvan de KerkhofMPJ, et al.Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years. Schizophr Bull2019; 45: 315–329. DOI: 10.1093/schbul/sby052.
3.
ForresterTSiskindDWinckelK, et al.Increasing clozapine dispensing trends in queensland, Australia 2004-2013. Pharmacopsychiatry2015; 48: 164–169. DOI: 10.1055/s-0035-1554713.
4.
Idänpään-HeikkiläJAlhavaEOlkinuoraM, et al.Agranulocytosis during treatment with chlozapine. Eur J Clin Pharmacol1977; 11: 193–198. DOI: 10.1007/bf00606409.
5.
KaneJHonigfeldGSingerJ, et al.Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry1988; 45: 789–796. DOI: 10.1001/archpsyc.1988.01800330013001.
BastiampillaiTGuptaAChanSK, et al.Changes for clozapine monitoring in the United States. Mol Psychiatry2016; 21: 858–860. DOI: 10.1038/mp.2016.66.
10.
MylesNMylesHXiaS, et al.Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand2018; 138: 101–109. DOI: 10.1111/acps.12898.
11.
ZhouJZhouNLiuQ, et al.Prevalence of neutropenia in US residents: a population based analysis of NHANES 2011-2018. BMC Publ Health2023; 23: 1254. DOI: 10.1186/s12889-023-16141-5.
12.
SchultePFJVeermanSRTBakkerB, et al.Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: can the regulations be relaxed?Schizophr Res2023. Online ahead of print. DOI: 10.1016/j.schres.2023.09.024.
13.
NorthwoodKMylesNClarkSR, et al.Evaluating the epidemiology of clozapine-associated neutropenia among people on clozapine across Australia and Aotearoa New Zealand: a retrospective cohort study. Lancet Psychiatr2024; 11: 27–35. DOI: 10.1016/s2215-0366(23)00343-7.
14.
LiXHZhongXMLuL, et al.The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Psychol Med2020; 50: 583–594. DOI: 10.1017/s0033291719000369.
15.
MylesNMylesHXiaS, et al.A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia. Aust N Z J Psychiatry2019; 53: 403–412. DOI: 10.1177/0004867419833166.
16.
HonigfeldG. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv1996; 47: 52–56. DOI: 10.1176/ps.47.1.52.
17.
LahdelmaLAppelbergB. Clozapine-induced agranulocytosis in Finland, 1982-2007: long-term monitoring of patients is still warranted. J Clin Psychiatry2012; 73: 837–842. DOI: 10.4088/JCP.11m07244.
18.
TirupatiSNageshOGulatiS. Benign ethnic neutropenia and clozapine treatment protocol in Australia. Aust N Z J Psychiatry2020; 54: 210–211. DOI: 10.1177/0004867419883024.
19.
OloyedeEBlackmanGWhiskeyE, et al.Clozapine haematological monitoring for neutropenia: a global perspective. Epidemiol Psychiatr Sci2022; 31: e83. DOI: 10.1017/s204579602200066x.
20.
WuSPowellVChintohA, et al.Safety of BEN guidelines in clozapine treatment: a Canadian perspective. Schizophr Res2024; 264: 451–456. DOI: 10.1016/j.schres.2024.01.021.
21.
OloyedeEWhiskeyECasettaC, et al.Relaxation of the criteria for entry to the UK clozapine central non-rechallenge database: a modelling study. Lancet Psychiatr2022; 9: 636–644. DOI: 10.1016/s2215-0366(22)00188-2.
22.
OloyedeEDzahiniOAbolouZ, et al.Clinical impact of reducing the frequency of clozapine monitoring: controlled mirror-image cohort study. Br J Psychiatry2023; 223: 382–388. DOI: 10.1192/bjp.2023.44.
23.
GirardinFRPoncetABlondonM, et al.Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis. Lancet Psychiatr2014; 1: 55–62. DOI: 10.1016/s2215-0366(14)70245-7.
24.
CastleDCopolovDSinghB, et al.Seven decades of antipsychotic drugs: why is the life of Australians with schizophrenia still so suboptimal?Aust N Z J Psychiatry2024; 58: 201–206. DOI: 10.1177/00048674231209840.
25.
GalletlyCCastleDDarkF, et al.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry2016; 50: 410–472. DOI: 10.1177/0004867416641195.
